Tumor CD20 Loss and Poor Outcome in Relapsed/Refractory (R/R) Diffuse Large B- Cell Lymphoma (DLBCL)

被引：0
|
作者：
Alchidiac, Jessy [1 ,2 ]
Hueso, Thomas [1 ]
Massard, Christophe [1 ]
Ribrag, Vincent [1 ]
Michot, Jean-Marie [1 ]
机构：
[1] Inst Gustave Roussy, Paris, France
[2] Lebanese Univ, Beirut, Lebanon
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
ABCL; relapsed/refractory non-Hodgkin Lymphoma; CD20; loss; CD20 weak expression; biopsy at relapse;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-119
引用
收藏
页码：S457 / S457
页数：1
相关论文
共 50 条
  • [21] Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL)
    Sinha, Rajni
    King, Nassoma
    Shenoy, Pareen J.
    Lechowicz, Mary Jo
    Bumpers, Kevin
    Hutcherson, Donald
    Arellano, Martha
    Langston, Amelia
    Kaufman, Jonathan L.
    Heffner, Leonard T.
    Waller, Edmund K.
    Flowers, Christopher R.
    Lonial, Sagar
    BLOOD, 2011, 118 (21) : 707 - 708
  • [22] Grading of Neurotoxicity in Patient with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study
    Maziarz, Richard T.
    Schuster, Stephen J.
    Romanov, Vadim V.
    Rusch, Elisha S.
    Signorovitch, James
    Ericson, Solveig G.
    Maloney, David G.
    Locke, Frederick L.
    BLOOD, 2018, 132
  • [23] Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
    Witzig, Thomas E.
    Maddocks, Kami J.
    De Vos, Sven
    Lyons, Roger M.
    Edenfield, William Jeffery
    Sharman, Jeff Porter
    Vose, Julie
    Yimer, Habte Aragaw
    Wei, Helen
    Chan, Edward M.
    Patel, Priti
    Di Simone, Christopher
    Gandhi, Mitul
    Vaughn, Jennifer
    Kolibaba, Kathryn
    Cheson, Bruce D.
    Samaniego, Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Sustained disease control and correlative analyses in tisagenlecleucel treated relapsed/refractory diffuse large B-Cell lymphoma patients (r/r DLBCL)
    Borchmann, P.
    Bachanova, V.
    Westin, J.
    Tam, C.
    Jaeger, U.
    McGuirk, J.
    Holte, H.
    Waller, E.
    Jaglowski, S.
    Bishop, M.
    Andreadis, C.
    Foley, S. R.
    Fleury, I.
    Teshima, T.
    Mielke, S.
    Salles, G.
    Ho, J.
    Izutsu, K.
    Maziarz, R.
    van Besein, K.
    Kersten, M. J.
    Wagner-Johnston, N.
    Kato, K.
    Corradini, P.
    Han, X.
    Agoulnik, S.
    Chu, J.
    Eldjerou, L.
    Pacaud, L.
    Schuster, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 238 - 238
  • [25] Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status
    Saverno, Kim
    Savill, Kristin M. Zimmerman
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Amoloja, Theresa
    Epperla, Narendranath
    Nastoupil, Loretta J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S464 - S464
  • [26] Prognostic value of CD20/CD73 ratio in sensitive and relapsed/refractory diffuse large B-cell lymphoma cell lines
    Gu, Juan J.
    Mavis, Cory
    Wang, Jessica
    Mandeville, Taylor
    Hernandez-Ilizaliturri, Francisco
    CANCER RESEARCH, 2023, 83 (07)
  • [27] Loss of CD20 expression in relapsed diffuse large b-cell lymphoma: Clinical significance of an uncommon pathological finding
    Mitra, Subhashis
    Mukherjee, Sanghamitra
    Bhattacharyya, Maitreyee
    Chakraborty, Hema
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2016, 59 (02) : 263 - 265
  • [28] Outcome in Unselected Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Following R-CHOP When Stem Cell Transplantation Is Not Feasible
    Kansara, Roopesh R.
    Savage, Kerry J.
    Villa, Diego
    Shenkier, Tamara
    Gerrie, Alina S.
    Klasa, Richard
    Hitz, Felicitas
    Scott, David W.
    Slack, Graham W.
    Gascoyne, Randy D.
    Connors, Joseph M.
    Sehn, Laurie H.
    BLOOD, 2014, 124 (21)
  • [29] Diffuse large B-cell lymphoma, leg type with loss of CD20 expression
    Thomas, A.
    Cibull, T.
    O'Malley, D.
    Billings, S.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2007, 34 (01) : 116 - 116
  • [30] DIM CD20 or CD5+ expression by flow cytometry is associated with a poor survival in patients with diffuse large B cell lymphoma (DLBCL) treated with either chop or CHOP-R
    Johnson, N. A.
    Sehn, L. H.
    Connors, J. M.
    Gascoyne, R. D.
    ANNALS OF ONCOLOGY, 2008, 19 : 107 - 107
12345